BR112022021893A2 - Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune - Google Patents

Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune

Info

Publication number
BR112022021893A2
BR112022021893A2 BR112022021893A BR112022021893A BR112022021893A2 BR 112022021893 A2 BR112022021893 A2 BR 112022021893A2 BR 112022021893 A BR112022021893 A BR 112022021893A BR 112022021893 A BR112022021893 A BR 112022021893A BR 112022021893 A2 BR112022021893 A2 BR 112022021893A2
Authority
BR
Brazil
Prior art keywords
combinations
methods
cancer
treatment
immune checkpoint
Prior art date
Application number
BR112022021893A
Other languages
English (en)
Portuguese (pt)
Inventor
Kurland John
Negro Alejandra
Chang Shao-Chun
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112022021893A2 publication Critical patent/BR112022021893A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112022021893A 2020-05-12 2021-05-12 Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune BR112022021893A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
PCT/EP2021/062695 WO2021228978A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Publications (1)

Publication Number Publication Date
BR112022021893A2 true BR112022021893A2 (pt) 2022-12-20

Family

ID=75977756

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021893A BR112022021893A2 (pt) 2020-05-12 2021-05-12 Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune

Country Status (12)

Country Link
US (3) US20220363762A1 (https=)
EP (1) EP4021940A1 (https=)
JP (2) JP7387912B2 (https=)
KR (1) KR20230009354A (https=)
CN (1) CN114729054A (https=)
AU (3) AU2021269832B2 (https=)
BR (1) BR112022021893A2 (https=)
CA (1) CA3158607A1 (https=)
IL (2) IL297640A (https=)
MX (1) MX2022006728A (https=)
TW (2) TW202535468A (https=)
WO (1) WO2021228978A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260077026A1 (en) * 2022-09-07 2026-03-19 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트
WO2025256641A1 (zh) * 2024-06-13 2025-12-18 江苏恒瑞医药股份有限公司 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087335A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
CN1745170A (zh) 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 生物活性材料的高压喷雾干燥
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
EP4245376A3 (en) * 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
US20180079814A1 (en) * 2015-04-01 2018-03-22 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
HRP20210602T1 (hr) * 2016-06-20 2021-05-14 F-Star Delta Limited Vezujuće molekule koje vežu pd-l1 i lag-3
KR20190057303A (ko) * 2016-09-27 2019-05-28 온콜로지, 인크. β2-당단백질 1의 수준에 기초한 바비툭시마브에 의한 암 치료 방법, 및 이를 위한 에세이
US11571459B2 (en) * 2017-04-03 2023-02-07 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
JP7055820B2 (ja) * 2017-05-26 2022-04-18 ブルーイン バイオサイエンシズ，インコーポレイテッド 化学塞栓療法剤
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US20210260051A1 (en) * 2018-06-14 2021-08-26 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
US20210254069A1 (en) * 2018-06-15 2021-08-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Also Published As

Publication number Publication date
TW202535468A (zh) 2025-09-16
MX2022006728A (es) 2022-06-09
JP2024016209A (ja) 2024-02-06
JP2023524359A (ja) 2023-06-12
KR20230009354A (ko) 2023-01-17
AU2024202963A1 (en) 2024-05-30
AU2021269832B2 (en) 2024-09-19
AU2021269832A1 (en) 2022-05-19
IL311936A (en) 2024-06-01
EP4021940A1 (en) 2022-07-06
US20210355224A1 (en) 2021-11-18
WO2021228978A1 (en) 2021-11-18
CN114729054A (zh) 2022-07-08
CA3158607A1 (en) 2021-11-18
IL297640A (en) 2022-12-01
TWI870592B (zh) 2025-01-21
JP7387912B2 (ja) 2023-11-28
AU2024202963B2 (en) 2025-11-20
US20240239893A1 (en) 2024-07-18
US20220363762A1 (en) 2022-11-17
TW202207976A (zh) 2022-03-01
AU2024266949A1 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
BR112022021893A2 (pt) Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CR20200467A (es) Agentes anticuerpos anti-cd25
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
BR112014018481A2 (pt) anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
MX2020012567A (es) Anticuerpos anti-ox40 y metodos de uso.
BR112016030686A2 (pt) anticorpos anti tau humanizados
CO2022001195A2 (es) Anticuerpos dirigidos contra dll3 y usos de los mismos
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
BR112022024084A2 (pt) Receptores de antígeno quiméricos específicos para p95her2 e usos dos mesmos
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
JOP20210169A1 (ar) أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري
EP4644427A3 (en) Manabodies and methods of using
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA202191666A1 (ru) Антитела к il-27 и их применение
BR112019007147A2 (pt) anticorpos anti-o1 e usos dos mesmos
BR112022026533A2 (pt) Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
MX2023008028A (es) Anticuerpos anti-pd-l1 y proteinas de fusion de estos.
DOP2025000290A (es) Anticuerpos cd163 o proteínas de unión
BR112023006989A2 (pt) Anticorpos biespecíficos anti-pd-1/cd40 e usos dos mesmos
EA201990222A1 (ru) Антитела к o2 и пути их применения
BR112023014582A2 (pt) Método de tratamento do câncer
CL2023003047A1 (es) Anticuerpo anti componente del complemento 1s (c1s)
BR112022009147A2 (pt) Métodos de tratamento do câncer e métodos para aumentar, potencializar ou estimular uma resposta ou função imune

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025009416-1 PROTOCOLO 870250038282 EM 12/05/2025 15:06.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]